31-01-2012 13:21 Ronald W. Hanson, Jr., MD lectures at the 11th Clinical Applications for Age Management Medicine in November 2011, in Las Vegas, Nevada This focused conference track cocentrated on regenerative and cell-based medicine continue to grow in use by physicians across the world. From platelet rich plasma to culture expanded stem cells, the need for information about the applications of these therapies to treat patients has never been greater. This track will focus on the latest developments in cell-based medicine with speakers who are driving the research and using these technologies as part of their everyday practice of medicine. For more information contact conference@agemed.org Visit our website at agemed.org

The rest is here:
The Use of Guided Bone Marrow Nucleated Cell Fraction Injections - Ronald W. Hanson, Jr., MD - Video

05-02-2012 05:11 Dr. Martin of MetroMD performs a bone marrow extraction procedure to harvest stem cells. The extracted bone marrow will be centrifuged to separate targeted stem cells and re-injected into the patient's injured joints. Questions? Please call the MetroMD Institute of Regenerative Medicine at (323) 285-5300 or email us at info@MetroMD.net. MetroMD.net

Read the rest here:
Bone Marrow Extraction Procedure to Harvest Stem Cells | MetroMD Los Angeles - Video

05-02-2012 11:27 MetroMD.net Dr. Martin explains why bone marrow is a better source than fat tissue for viable stem cells in your own body. Questions? Please call the MetroMD Institute of Regenerative Medicine at (323) 285-5300 or email us at info@MetroMD.net. Los Angeles

See the original post:
What Is The Best Source for Stem Cells- Bone Marrow or Fat Tissue? | MetroMD Los Angeles - Video

18-01-2012 23:09 NewHopeForAging.info - Beverly Hills Plastic Surgeon, Dr. Nathan Newman reveals the truth about the Adult Stem Cell Technology...and the ONLY product on the market with it Luminesce, by Jeunesse. Order it at: NewHope.JeunesseGlobal.com or call 561.779.0000

Continued here:
Dr Newman Exposes The Truth about Adult Stem Cells - Video

20-12-2011 08:50 If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells. Adult stem cell therapy for COPD, Emphysema, and Pulmonary fibrosis.

See the original post here:
Adult Stem Cell Treatments for COPD - Real patient results, USA Stem Cells - Marian H. Testimonial - Video

To: HEALTH AND NATIONAL EDITORS

VIRGINIA BEACH, Va., Feb. 20, 2012 /PRNewswire-USNewswire/ -- Rony Thomas, President and CEO of LifeNet Health, is presenting at the 7th Annual Stem Cell Summit in New York City on February 21, 2012. Mr. Thomas will be presenting on LifeNet Health's broad offerings of current and future regenerative biologic-based products. Mr. Thomas will also focus on the multiple new capabilities and technology platforms of the LifeNet Health Institute of Regenerative Medicine.

(Photo: http://photos.prnewswire.com/prnh/20120220/DC55479)

"The use of a variety of forms of donated tissues has worked for decades to save lives and restore health in many surgical disciplines. Now we are on the cusp of developing cellular therapies, tissue engineering and new medical applications for allografts to treat disease and assist in the development of lifesaving drugs. The opening of the LifeNet Health Institute of Regenerative Medicine this year will signal our commitment to future development in the cellular therapies arena," stated Mr. Thomas. Thomas will further focus on two new areas of development; Human Basement Membranes in zeno-free culture of consented Human mRNA Reprogrammed Induced Pluripotent Stem Cells and Induced Pluripotent Stem Cells (iPSc) derived using non-integrating mRNA reprogramming technology from fully consented queryable human donor banked system.

Mr. Thomas was also recently invited to and attended a White House Summit to discuss ways in which technology and innovation can drive employment opportunities for Virginia, where LifeNet Health and the Institute are located. The meeting of key CEOs with the Obama Administration was to gain insight and input on the job market and technology as a driver to local, state, and national economies. Thomas stated, "Our foray into regenerative medicine should not only impact our state and local economy, but provide medical benefits to patients and drug companies across the globe."

The annual Stem Cell Summit brings key leaders in the medical, scientific and business innovators in this growing space of technology and regenerative medicine. LifeNet Health is pleased to be joining the Summit for the first time in 2012 as they look for key partnerships and collaboration in the discovery of cell-based therapies for a broad spectrum of medical applications in orthopedics, trauma, dental, craniomaxillofacial (CMF), plastics, and cardiovascular surgery.

LifeNet Health helps to save lives and restore health for thousands of patients each year. We are the world's most trusted provider of transplant solutions, from organ procurement to new innovations in bio-implant technologies and cellular therapies--a leader in the field of regenerative medicine, while always honoring the donors and healthcare professionals that allow the healing process.

The LifeNet Health Institute of Regenerative Medicine is a division of LifeNet Health located in Virginia Beach, Virginia. The Institute's labs will be expanding as new facilities are under construction and planned to be completed in the fall of 2012. Once completed and fully functional, the Institute will house over 50 medical, scientific, and research staff members. The focus will be on the science of developing regenerative medicine products for patients all over the world, and will serve as a global center of excellence for research and development focused on cellular therapies, tissue engineering, and new medical applications for allografts to maximize the gift of donation.

SOURCE LifeNet Health

-0-

See the rest here:
LifeNet Health is Presenting at the 7th Annual Stem Cell Summit in New York on February 21, 2012

The day – Valentine’s Day, as it happened – began in a whirl of coffee cups, bustling dogs and homework, then a brisk walk around the block – in other words, business as usual for a UC Irvine couple who are a high-profile science team engaged in cutting-edge stem-cell research.

Brian Cummings and Aileen Anderson, whose stem-cell treatment for spinal cord injury is being tested on patients in Switzerland, say their office – only a short walk from their home on the UCI campus – has a family feel as well.

At UCI’s recently constructed Stem Cell Research Center, they supervise a crew of young students and technicians whose bond with their mentors is so close that they call themselves the “Andermings.”

“I suppose it’s like having an orphanage,” Cummings joked as he prepared for the day ahead.

It would include a lengthy meeting with the Andermings on how best to grow human embryonic stem cells without animal-cell contamination, a critique of a doctoral candidate’s presentation of potentially significant new findings and a session with Alzheimer’s researchers at an institute called UCI MIND.

But first, Cummings, Anderson and their two dogs – Chesapeake and Indiana – had to get the couple’s 6-year-old daughter, Camryn, to school.

After Camryn finished her homework (completed strategically a day in advance, leaving more time for afternoon play), they took the long way round to the Montessori school, also easy walking distance from their home.

Along the way, they encountered another faculty couple, from the German department, and their dog. They stopped with Camryn, giggling as the dogs rolled and tumbled on a neighbor’s lawn.

•••

Cummings, 47, and Anderson, 45, together since they were both undergrads at the University of Illinois, say living and working with each other comes naturally.

“People say, ‘Do I need a break from her?’ ” Cummings said as he wrangled the dogs.

“More people say, ‘Do you need a break from him?’ ” Anderson replied.

Later, the conversation transitions into a science meeting as the two take the 20-minute walk past UCI’s Ecological Preserve and into the Sue and Bill Gross Stem Cell Research Center. The energy-efficient building, with an open design to encourage chance meetings among scientists, houses a roster of high-powered researchers as well as their experimental subjects: rodents.

The center was seeded by $27 million in state stem-cell funding and $10 million from donors Bill and Sue Gross. The building was completed in 2010.

Now, researchers working there cultivate lines of human embryonic stem cells that can grow into a variety of cell types, from brain cells to liver and heart cells.

The ability to coax stem cells into many forms – and with it the potential to treat Alzheimer’s, paralysis and a long list of diseases – is fueling an explosion of research around the nation and across the state.

Anderson and Cummings showed that their stem-cell treatment, using cells derived from aborted fetuses, allowed partially paralyzed rats to walk again. The rat’s recovery was revealed in a dramatic before-and-after video.

So far, the human trial of the treatment in Switzerland is showing no ill effects on patients, Cummings said.

But stem-cell research is buffeted by political controversy, funding uncertainties and, sometimes, attacks by stem-cell research opponents.

The trial of the treatment developed by Cummings and Anderson with their collaborators, StemCells Inc., was the first of its kind in the world when it was announced in 2010.

In some ways, that made the family – and their team – a target.

Concerns about possible intruders prompted the couple to place a camera at their front door. Cummings’ tires have been slashed, he said, though he doesn’t know if that was the work of people who oppose the harvesting of human embryonic stem cells, animal-rights activists (angered by experiments on rodents) or perhaps a disgruntled student.

At the moment, Cummings and Anderson are running five research programs and leading 17 researchers. All of it is funded by $2.2 million in grants, much of it from California Institute for Regenerative Medicine, or CIRM.

Created by voter initiative – Proposition 71 in 2004 – CIRM is California’s $3 billion answer to federal restrictions on funding for stem-cell research. Those restrictions were started by the Bush administration and eased, but not eliminated, under President Obama.

Cummings said opposition to their research is based, in part, on incorrect assumptions.

A big one is that the research involves the destruction of embryos. In reality, they work with balls of cells created at an earlier stage of human development, called blastocysts – a distinction many opponents do not draw.

“Embryonic stem cells don’t come from embryos,” he said. “And they never have.”

The raw material comes from fertility clinics and otherwise would be discarded.

Cummings says those who say that such research is immoral have it wrong.

“The argument is backward,” he said. “It’s immoral to throw away this stuff and not use it to help someone.”

••

During their meeting with the Andermings, project leader Hal Nguyen described the group’s plan to grow a series of stem-cell cultures and check a compelling question: Is some of a stem cell’s transformation guided by the microscopic environment in which it dwells, or is it entirely dictated by the cell’s internal workings?

“The plan is in the email,” Nguyen told Anderson.

“Dude, I have 400 emails,” Anderson said.

The group’s task was meant to answer a classic nature-nurture question, Anderson said. In this case, “nature” is the DNA coding in the stem cell itself, while “nurture” is the cellular environment, with all its floating nutrients and chemical signals.

“Will that environment, the extrinsic factor, trump anything the cell can do?” Anderson had wondered earlier. “Or is the intrinsic programming of the cell the principal determinant? Is that the main driving factor?”

Cummings stood by in the tiny meeting room while the researchers batted around their questions and answers. He said Anderson, a spinal cord specialist, was the expert in this arena, though he couldn’t help piping in during a discussion of the medium in which the cells would be grown.

“You’re comparing two different medias, too?” Cummings asked.

“We all know what we’re talking about,” Anderson told him. “Don’t interrupt.”

Then it was on to a larger, mostly empty meeting room where Sheri Peterson, a doctoral candidate, wanted to test her presentation on Cummings and Anderson.

Her eventual target is an advancement committee that will determine her future. The presentation will be crucial in her quest for a Ph.D.

Peterson ran through an array of slides projected on a large screen to reveal her findings. Inflammation of damaged tissue being regenerated in rats, she said, might be eased or worsened simply by manipulating proteins surrounding the regenerating cells.

Again, the topic was in Anderson’s wheelhouse.

“My notes said, ‘Nicely done,’ ” Cummings told Peterson.

“He’s not an aficionado,” Anderson said.

The husband-and-wife researchers then provided her with a detailed, slide-by-slide critique.

•••

Cummings’ expertise centers on traumatic brain injury. But he also is an expert at the complex task of marshaling grant funding. On his office wall, a whiteboard densely covered with writing tells the story: Cummings must police incoming and outgoing grants like an air traffic controller, timing the grants and the work they fund to match years of employment for graduate students and staff members.

The grants come and go over months and years, and so do the students and staff. Get the timing wrong, and you might have funding with no researchers, or researchers with nothing to do.

“At UCI, I’m like a small-business owner,” Cummings said.

Over a hasty lunch in his office (cold sandwiches grabbed during a trip, with Anderson, to a nearby campus snack shop), Cummings spoke of the merging of home and office life.

Writing up grant requests takes up both researchers’ time. Often, as they write, Camryn is playing in the background, whether at home or at the office. And research collaborators can show up wanting to conduct interviews at any time, holidays included.

“I did draw a line in the sand at Christmas Eve,” Anderson said.

Cummings knows such stress has driven other husband-and-wife teams into open conflict. But that just isn’t his and Anderson’s style. In fact, he said, keeping a scientific perspective, even at home, might help keep things calm.

“There’s no need to be yelling and shouting at each other because we don’t think that way,” he said. “You’re supposed to believe nothing until you prove it.”

That doesn’t mean they don’t differ, sometimes strongly, over scientific details.

“They don’t always agree with each other, and that’s good,” said Brittany Greer, an intern in their lab and an Anderming.

Nurturing the students and young scientists is part of the pleasure of doing science for both halves of the research couple, Anderson said.

“You start to look at this crowd of people as your second family,” she said. “They’re your kids. That is fun and rewarding for sure.”

You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.

Continue reading here:
Stem-cell scientists find right chemistry

WFMY News 2

Wake Forest Biotech Place Will House Hundreds of Medical Researchers WFMY News 2 Biotechnology and medical research is helping that happen. Wake Forest Biotech Place opens Tuesday in Piedmont Triad Research Park. It's called a state-of-the-art, world-class, 242000 square-foot, biotechnology research and innovation center. and more »

Source:
http://news.google.com/news?q=biotechnology&output=rss

Ghana Business News

Ghana's Biosafety Law finally receives Presidential Assent BusinessGhana The Law, from the Biosafety Act, 831, 2011 will enable Ghana to allow the application of biotechnology in food crop production involving Genetically Modified Organisms (GMOs) to enter food production. It will also ensure an adequate level of production ... Ghana Now Has Biosafety LawPeace FM Online all 5 news articles »

Source:
http://news.google.com/news?q=biotechnology&output=rss

Talk of the Sound

Sound Shore Medical Center Resident Receives Young Scientist Award Talk of the Sound Recently, she was in Barcelona, Spain to attend the World Congress on Debates & Consensus in Bone, Muscle & Joint Diseases where she presented her Abstract, “Molecular Genetics in the Diagnosis of Calpainopathy”. Even more impressive, Dr. Poste ...

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

Via Scoop.it – inPharmatics
Privacy controlled & safe social network for Healthcare launched by Jonathan Schwartz, Ex-CEO Sun Microsystems. The networks available at http://www.carezone.com  Connects Caregivers With family members and allows health-care workers share information about aging or ill parents, spouses and children
Via http://www.bloomberg.com

Source:
http://microarray.wordpress.com/feed/

Source:
http://microarray.wordpress.com/feed/

The mainstream media waxed enthusiastic last month when a California hESC clinical trial reported positive results dealing with blindness.

The report was first published account of a human trial of embryonic stem cell based therapy and involved Advanced Cell Technology, which is headquartered in Santa Monica, Ca. Despite a glowing reception of the trial's results, the firm is years away from being able to market the therapy at a profit – if it ever can do so.

The firm's chief scientific officer, Robert Lanza, moved quickly, however, to capture some monetary gain from the news, which was announced in a press release Jan. 23 by ACT.

On Jan. 23 and 24, Lanza sold 7.7 million shares in ACT for $1.5 million, according to SEC documents. He sold the stock at 18 and 19 cents a share. That compares to an ACT price of about 8 cents at the end of 2011. Lanza still holds 26 million shares in the firm. The acquisition price of the stocks is unknown.

There is nothing to suggest anything untoward about Lanza's sale. But it is a reminder that creating a successful stem cell therapy is about making money. Without a profit, there will be no therapy, as Geron reminded everyone last November when it dropped its longstanding hESC trial.

The California Stem Cell Report has asked Lanza if he has any comments about the sale of the stock. We will carry his remarks verbatim when we receive them.

The Seeking Alpha web site appears to have been the first to report the sale. Here is their complete item.

"Advanced Cell Technology, Inc. (ACTC.OB): ACTC is a development-stage biotech focused on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. On Wednesday, Chief Science Officer Robert Lanza filed SEC Form 4 indicating that he sold 7.7 million shares for $1.5 million, ending with 26.0 million shares after that sale. ACTC shares have rallied strongly since the beginning of the year, up from 8.2 cents at the end of last year to currently in 14-15c range after rising above 20c just earlier this week."

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

The California stem cell agency this week performed its semi-annual public disclosure of its contracts with outside firms, the second largest item in its operational budget of $18.5 million.

The contracts are scheduled to run about $3.3 million this fiscal year, according to the budget approved last May. That figure is up about 18 percent from the previous year.

According to the contract information posted this week, the two largest contracting expenditures this year are for information technology work, including the ongoing struggles with the grants management system – $1.3 million – and legal help – $887,282. The figures were compiled by the California Stem Cell Report. CIRM did not provide totals.

Outside contracts are second to the cost of salaries and benefits at the agency. One reason for the size of the contracting expense is the small size of the CIRM staff, which is now about 50.

The contracting information will be presented to the CIRM directors' Governance Subcommittee next Friday. The committee is being asked to approve an increase in the contract with Kutir Corp., from $250,000 to $470,000. By the end of 2011, CIRM had already paid out $219,680 to Kutir. The firm provides software development services.

Infonetica, which provides technology advice, would also see an increase from $236,060 to $300,000, under the staff proposal.

A staff memo to the board said,

"(Kutir's) services are key as CIRM continues to progress in automating its grants management systems to meet the requirements of both new RFAs as well as ongoing reporting obligations.""

The public can participate in the Governance meeting at locations in San Francisco, Sacramento, Irvine, Los Angeles, South San Francisco and La Jolla. Specific addresses can be found on the agenda.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

The California stem cell agency today said the seven-year-old "audacious vision" of voters when they created the $3 billion research effort "is still possible."

The comment was made in an item on the agency's blog by Amy Adams, the agency's communications manager.

Her entry point was an opinion piece in The Sacramento Bee on Sunday exploring some of the ins and outs of the agency. Among other things, CIRM President Alan Trounson was quoted by writer David Lesher as "optimistically" predicting successful California stem cell treatments in five years.

Adams wrote,

"Lesher makes clear that there are many challenges ahead in bringing new therapies to patients: he said of the voters who created CIRM, 'It was pretty audacious of them in 2004 to try to create another economic driver like Silicon Valley and save lives at the same time.'

"And while the vote was audacious, we agree with his conclusion that despite risks and challenges that vision is still possible." 

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

The California public is being given a chance to weigh in with anonymous comments about what they think of the performance of the $3 billion California stem cell agency.

Their opinions are being sought by a blue-ribbon, Institute of Medicine panel. The IOM is being paid $700,000 by the agency to examine its operations.

The questions include the importance of stem cell research and CIRM's role, its openness and transparency, an assessment of its grant programs and how it should share information with the public, suggestions for improvements and more.

The online form was posted recently on the IOM web site and can be found here. The deadline for submissions is March 19.

The IOM also has survey forms for academic and non-profit CIRM grant recipients, CIRM grant recipients that are businesses(which the IOM calls "industry partners") and "leadership of CIRM-funded institutions." The deadline for those is March 19 as well.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the 7th Annual New York Stem Cell Summit at Bridgewaters New York City on Tuesday, February 21, 2012 at 8:48 a.m. ET. Dr. West will provide an update and new information on the Company's manufacturing technologies and cell-based therapeutics in development. The presentation will be available online at http://www.biotimeinc.com.

The annual New York Stem Cell Summit provides investors, industry, practitioners, and analysts with the latest developments and investment opportunities in the stem cell marketplace.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is developed through subsidiaries focused on specific fields of applications. BioTime develops and markets research products in the field of stem cells and regenerative medicine, including a wide array of proprietary ACTCellerate™ cell lines, culture media, and differentiation kits. BioTime's wholly owned subsidiary ES Cell International Pte. Ltd. has produced clinical-grade human embryonic stem cell lines that were derived following principles of Good Manufacturing Practice and currently offers them for use in research. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences, Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. Cell Cure's minority shareholder Teva Pharmaceutical Industries has an option to clinically develop and commercialize Cell Cure's OpRegen™ retinal cell product for use in the treatment of age-related macular degeneration. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-DxTM currently being developed for the detection of cancer in blood samples, therapeutic strategies using vascular progenitor cells engineered to destroy malignant tumors. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's newest subsidiary, LifeMap Sciences, Inc., is developing an online database of the complex cell lineages arising from stem cells to guide basic research and to market BioTime's research products. In addition to its stem cell products, BioTime develops blood plasma volume expanders, blood replacement solutions for hypothermic (low-temperature) surgery, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product, Hextend®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime, ReCyte Therapeutics, Cell Cure, OrthoCyte, OncoCyte, BioTime Asia, LifeMap Sciences, and ESI can be found on the web at http://www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list:
http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts

See the article here:
BioTime CEO Michael D. West to Present at New York Stem Cell Summit

16-02-2012 20:19 Many of our patients travel to Guangzhou from all over the world for medical treatment and tourism. China medical tourism can help with becoming a patient, travel arrangements and language assistance. If you want to know more about our services, please browse the web:htttp://www.medicaltourism.hk/ or mail to us: giels-x@medicaltourism.hk firstcare-china@hotmail.com Adult stem cells provide real improvement for cirrhosis patients Breakthrough adult stem cell research has shown that stem cells are able to regenerate and repair damaged or destroyed liver cells. For patients with cirrhosis, this means improved liver function, decreased pain and a significantly improved quality of life. Stem cell therapy offers the safest and most effective treatment alternative for liver cirrhosis and it is quickly becoming a preferred treatment in Asia. China medical tourism offers unique access to the best stem cell therapies available at leading medical facilities. Supporting data and statistics Three out of every four patients treated experienced a significant improvement in their condition following stem cell treatment. The following clinical results were observed: •Improved liver function •Decreased pain •Improved values for liver function, PLT (blood platelet) and blood ammonia You may see improvements during your hospitalization due to neurotrophic factors released during the stem cell transplantation, which stimulate nerve activity; new cells will grow for up to six months after you ...

Original post:
China medicdal tourism-- Cirrhosis--Stem cells therapy 1.mp4 - Video

SAN BRUNO, Calif., Feb. 16, 2012 /PRNewswire/ -- Cord Blood Registry (CBR) is the exclusive partner for a growing number of clinical researchers focusing on the use of a child's own cord blood stem cells to help treat pediatric brain injury and acquired hearing loss. To ensure consistency in cord blood stem cell processing, storage and release for infusion, three separate trials have included CBR in their FDA-authorized protocol—including two at the University of Texas Health Science Center at Houston (UTHealth) working in partnership with Children's Memorial Hermann Hospital, and a third at Georgia Health Sciences University, home of the Medical College of Georgia (MCG). This makes CBR the only family stem cell bank pairing researchers with prospective patients for these studies. 

(Logo: http://photos.prnewswire.com/prnh/20120216/AQ54476LOGO)

"Partnering with a series of specialists who want to research the use of a child's own newborn blood stem cells on a variety of disease states allows CBR to help advance medical research for regenerative therapies by connecting the child whose family banked with CBR to appropriate researchers," said Heather Brown, MS, CGC, Vice President of Scientific & Medical Affairs at Cord Blood Registry.  "The pediatric specialists from UTHealth, Children's Memorial Hermann Hospital, and Georgia Health Sciences University are at the forefront of stem cell research as they evaluate cord blood stem cells' ability to help facilitate the healing process after damage to nerves and tissue."

Hearing Loss and Traumatic Brain Injury Clinical Trials Break New Ground

Sensorineural hearing loss affects approximately 6 per 1,000 children by 18 years of age, with 9 percent resulting from acquired causes such as viral infection and head injury.(1,2,3)  The Principal Investigator of the hearing loss study is Samer Fakhri, M.D., surgeon at Memorial Hermann-Texas Medical Center and associate professor and program director in the Department of Otorhinolaryngology – Head & Neck Surgery at UTHealth.  He is joined by James Baumgartner, M.D., sponsor of the study and guest research collaborator for this first-of-its-kind FDA-regulated, Phase 1 safety study of the use of cord blood stem cells to treat children with acquired hearing loss. The trial follows evidence from published studies in animals that cord blood treatment can repair damaged organs in the inner ear. Clients of CBR who have sustained a post-birth hearing loss and are 6 weeks to 2 years old may be eligible for the year-long study. "The window of opportunity to foster normal language development is limited," said James Baumgartner, M.D.  "This is the first study of its kind with the potential to actually restore hearing in children and allow for more normal speech and language development."

Although the neurologic outcome for nearly all types of brain injury (with the exception of abuse) is better for children than adults,(4,5) trauma is the leading cause of death in children,(6) and the majority of the deaths are attributed to head injury.(7) Distinguished professor of pediatric surgery and pediatrics at UTHealth, Charles S. Cox, M.D. launched an innovative study building on a growing portfolio of research using stem cell-based therapies for neurological damage. The study will enroll 10 children ages 18 months to 17 years who have umbilical cord blood banked with CBR and have suffered a traumatic brain injury (TBI) and are enrolled in the study within 6-18 months of sustaining the injury. Read more about the trial here.

"The reason we have become interested in cord blood cells is because of the possibility of autologous therapy, meaning using your own cells. And the preclinical models have demonstrated some really fascinating neurological preservation effects to really support these Phase 1 trials," says Charles S. Cox, M.D., principle investigator of the trial. "There's anecdotal experience in other types of neurological injuries that reassures us in terms of the safety of the approach and there are some anecdotal hints at it being beneficial in certain types of brain injury."

Georgia Health Sciences University (GHSU) Focuses on Cerebral Palsy

At the GHSU in Augusta, Dr. James Carroll, professor and chief of pediatric neurology, embarked on the first FDA-regulated clinical trial to determine whether an infusion of stem cells from a child's own umbilical cord blood can improve the quality of life for children with cerebral palsy. The study will include 40 children whose parents have stored their cord blood at CBR and meet inclusion criteria. 

"Using a child's own stem cells as a possible treatment is the safest form of stem cell transplantation because it carries virtually no threat of immune system rejection," said Dr. Carroll. "Our focus on cerebral palsy breaks new ground in advancing therapies to change the course of these kinds of brain injury—a condition for which there is currently no cure."

Cerebral palsy, caused by a brain injury or lack of oxygen in the brain before birth or during the first few years of life, can impair movement, learning, hearing, vision and cognitive skills. Two to three children in 1,000 are affected by it, according to the Centers for Disease Control.(8)

Cord Blood Stem Cell Infusions Move From the Lab to the Clinic

These multi-year studies are a first step to move promising pre-clinical or animal research of cord blood stem cells into clinical trials in patients. Through the CBR Center for Regenerative Medicine, CBR will continue to partner with physicians who are interested in advancing cellular therapies in regenerative applications.

"The benefits of cord blood stem cells being very young, easy to obtain, unspecialized cells which have had limited exposure to environmental toxins or infectious diseases and easy to store for long terms without any loss of function, make them an attractive source for cellular therapy researchers today," adds Brown. "We are encouraged to see interest from such diverse researchers from neurosurgeons to endocrinologists and cardiac specialists."

About CBR

CBR® (Cord Blood Registry®) is the world's largest and most experienced cord blood bank.  The company has consistently led the industry in technical innovations and supporting clinical trials. It safeguards more than 400,000 cord blood collections for individuals and their families. CBR was the first family bank accredited by AABB and the company's quality standards have been recognized through ISO 9001:2008 certification—the global business standard for quality. CBR has also released more client cord blood units for specific therapeutic use than any other family cord blood bank. Our research and development efforts are focused on helping the world's leading clinical researchers advance regenerative medical therapies. For more information, visit http://www.cordblood.com.

(1)  Bergstrom L, Hemenway WG, Downs MP. A high risk registry to find congenital deafness. Otolaryngol Clin North Am. 1977;4:369-399.
(2)  Billings KR, Kenna MA. Causes of pediatric sensorineural hearing loss: yesterday and today. Arch Otolaryngol Head Neck Surg. 1999 May;125(5):517-21.
(3)  Smith RJ, Bale JF Jr, White KR. Sensorineural hearing loss in children. Lancet. 2005;365(9462):879-890.
(4)  Faul M, Xu L, Wald MM, Coronado VG. Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths. Atlanta (GA): Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2010.
(5)  Schnitzer, Patricia, PH.D., "Prevention of Unintentional Childhood Injuries", American Academy of Family Physicians, 2006.
(6)  Centers for Disease Control and Prevention, "10 Leading Causes of Death, United States, 1997-2007", WISQARS, National Center for Health Statistics (NCHS), National Vital Statistics System
(7)  Marquez de la Plata, Hart et al, National Institutes of Health, "Impact of Age on Long-term Recovery From Traumatic Brain Injury", Arch Phys Med Rehabilitation, May 2008.
(8)  Centers for Disease Control and Prevention, http://www.cdc.gov/Features/dsCerebralPalsy, accessed February 6, 2012

Continued here:
Groundbreaking Clinical Trials Study Cord Blood Stem Cells to Help Treat Brain Injury and Hearing Loss

Posted on February 17, 2012, Friday

KUCHING: Organic solutions company Juice Beauty is introducing three new products in its Stem Cellular Repair line to the public, incorporating technology and science in delivering the new products.

“The three products, namely Stem Cellular Repair Moisturiser, Stem Cellular Repair Eye Treatment and Stem Cellular Repair Booster Serum work at the cellular level to repair damage and increase cellular proliferation,” explained Juice Beauty retail outlet manager, Shirley Ann Tan.

The products were noted to have used the brand’s own proprietary blend of organic fruit stem cells injected into its clinically validated antioxidant rich organic juice base to help decrease DNA damage and accelerate cellular proliferation.

Tan stated that Juice Beauty products were antioxidant-rich and made from 100 per cent organic juices. The formulations were protected from environmental contamination with high tech airtight pump jars.

The manager added, “The reason we are so intent in creating organic products is that we want people to avoid using harmful chemicals in their skin care range for health purposes. People with eczema, skin problems and allergies could feel free to try out our organic products.”

Juice Beauty’s boasts its patent-pending juice base which does not have any drying effect on the skin or suffocate the skin as alcohol- or petroleum-based products do.

“Using an organic juice base provides the benefit of having every drop of the product feed your skin,” she highlighted.

The new products are currently available at Juice Beauty’s outlet at tHe Spring Mall.

<< Previous Entry - Next Entry >>

Read the original post:
Juice Beauty’s to boost organic skin care further with Stem Cellular Repair line